Difference between revisions of "David Haslam (GP and obesity specialist)"
m |
|||
| Line 2: | Line 2: | ||
Dr David W Haslam is a general practitioner with a special interest in obesity and and cardiometabolic disease. He is a physician in Obesity Medicine at the [[Centre for Obesity Research]] at Luton & Dunstable Hospital, and Chair of the UK's [[National Obesity Forum]] (NOF). <ref> National Obesity Forum, [http://www.nationalobesityforum.org.uk/about-us/the-nof-trustees-mainmenu-159/122-dr-david-haslam.html Dr David Haslam], last accessed 6 October 2010. </ref> | Dr David W Haslam is a general practitioner with a special interest in obesity and and cardiometabolic disease. He is a physician in Obesity Medicine at the [[Centre for Obesity Research]] at Luton & Dunstable Hospital, and Chair of the UK's [[National Obesity Forum]] (NOF). <ref> National Obesity Forum, [http://www.nationalobesityforum.org.uk/about-us/the-nof-trustees-mainmenu-159/122-dr-david-haslam.html Dr David Haslam], last accessed 6 October 2010. </ref> | ||
| + | == Activities == | ||
| + | |||
| + | === Debate over obesity drugs efficacy === | ||
| + | |||
| + | On 19 Nov 2007 a new study reported in the British Medical Journal (BMJ) showed that anti-obesity treatments frequently failed to promote weight loss. Researchers had reviewed data and concluded orlistat, sibutramine and rimonabant were of only ‘modest’ help in long-term weight loss. | ||
| + | |||
| + | :Average weight loss was less than 5%, below the thresholds for recommending a continuation of therapy by NICE. NICE advises anti-obesity drugs should be discontinued if patients have not lost at least 5% of their initial body weight after three months. | ||
| + | |||
| + | :Study leader Professor [[Gareth Williams]], professor of medicine at the [[University of Bristol]], said the studies showed the jury was still out on the long-term efficacy and safety of anti-obesity treatments. He added that they should not be given to patients who cannot lose weight through lifestyle changes alone. | ||
| + | |||
| + | :‘If patients can’t get on and take responsibility for their own lives, then flinging a pill at them is not going to do any useful work at all,’ he said. | ||
| + | |||
| + | :Professor Williams also warned of ‘insidious collateral damage’ if GSK was successful in its bid to make orlistat available over the counter in Europe. | ||
| + | |||
| + | :Dr David Haslam, chair of the National Obesity Forum, slammed the BMJ meta-analysis for being ‘full of errors’ and called it a ‘very bad’ paper. ‘Five percent weight loss is very clinically significant. What they are doing here is actually looking at average weight loss and some may not lose any weight but others may lose 10 or 20%.’Dr Haslam supported moves to make Orlistat available over the counter. | ||
| + | <ref>[http://www.pulsetoday.co.uk/story.asp?sectioncode=23&storycode=4115938&c=2 . GPs divided on obesity drugs efficacy] Nigel Praities, 16 November 2007, PULSE,accessed 29 November 2007</ref> | ||
==Affiliations== | ==Affiliations== | ||
Revision as of 23:20, 7 October 2010
Dr David W Haslam is a general practitioner with a special interest in obesity and and cardiometabolic disease. He is a physician in Obesity Medicine at the Centre for Obesity Research at Luton & Dunstable Hospital, and Chair of the UK's National Obesity Forum (NOF). [1]
Contents
Activities
Debate over obesity drugs efficacy
On 19 Nov 2007 a new study reported in the British Medical Journal (BMJ) showed that anti-obesity treatments frequently failed to promote weight loss. Researchers had reviewed data and concluded orlistat, sibutramine and rimonabant were of only ‘modest’ help in long-term weight loss.
- Average weight loss was less than 5%, below the thresholds for recommending a continuation of therapy by NICE. NICE advises anti-obesity drugs should be discontinued if patients have not lost at least 5% of their initial body weight after three months.
- Study leader Professor Gareth Williams, professor of medicine at the University of Bristol, said the studies showed the jury was still out on the long-term efficacy and safety of anti-obesity treatments. He added that they should not be given to patients who cannot lose weight through lifestyle changes alone.
- ‘If patients can’t get on and take responsibility for their own lives, then flinging a pill at them is not going to do any useful work at all,’ he said.
- Professor Williams also warned of ‘insidious collateral damage’ if GSK was successful in its bid to make orlistat available over the counter in Europe.
- Dr David Haslam, chair of the National Obesity Forum, slammed the BMJ meta-analysis for being ‘full of errors’ and called it a ‘very bad’ paper. ‘Five percent weight loss is very clinically significant. What they are doing here is actually looking at average weight loss and some may not lose any weight but others may lose 10 or 20%.’Dr Haslam supported moves to make Orlistat available over the counter.
Affiliations
- National Obesity Forum - Chair
- Counterweight - board member
- Experts in Severe and Complex Obesity
- Robert Gordon University, Aberdeen - Visiting Professor
- Chester University - Visiting Professor [3]
- LighterLife UK Ltd - Chair of Medical Advisory Board [4]
- Foundations - Chair. Foundations is a charity that aims to provide the foundation of healthy diet and lifestyle in schools and in Primary Care, to prevent obesity and eating disorders.
- Bedfordshire and Hertfordshire Postgraduate Medical School - Staff [5]
- PCOS UK (the clinical wing of Verity, the charity for sufferers of Polycystic Ovarian Syndrome) - executive director and member of the Executive Council [6]
- 76 Harley Street - led its obesity services (dates needed)
- Primary Care Cardiovascular Journal, and the British Journal of Cardiology - member of both editorial boards [7]
- iGlobalFitness - chairman, Medical Advisory Board, appointed 24 September 2010. iGlobalFitness describe themselves as 'the sustainable wellness experts'. [8]
Books
- Maguire, Terry., and Haslam, D. (date), The Obesity Epidemic and Its Management: A Textbook for Primary Healthcare Professionals on the Understanding, Management and Treatment of Obesity. London, England, Pharmaceutical Press.
- Haslam, D., and Haslam, F., (2009) Fat, Gluttony and Sloth, Obesity in Art, Literature and Medicine. Liverpool, England, Liverpool University Press.
Resources
Notes
- ↑ National Obesity Forum, Dr David Haslam, last accessed 6 October 2010.
- ↑ . GPs divided on obesity drugs efficacy Nigel Praities, 16 November 2007, PULSE,accessed 29 November 2007
- ↑ National Obesity Forum, Dr David Haslam, last accessed 6 October 2010.
- ↑ LighterLife, Professor David Haslam, last accessed 6 October 2010.
- ↑ Bedfordshire and Hertfordshire Postgraduate Medical School, Staff Profile Dr David W Haslam, MB BS DGM, accessed 5 October 2010.
- ↑ PCOS UK Executive Council , accessed 6 October 2010.
- ↑ Bedfordshire and Hertfordshire Postgraduate Medical School, Staff Profile Dr David W Haslam, MB BS DGM, accessed 5 October 2010.
- ↑ iGlobalFitness appoint Prof David Haslam and Dr Matthew Capehorn to Medical Advisory Board , press release 24 September 2010, via Responsesource, Nilmot PR, accessed 6 October 2010.
